or Try an Advanced Search...

    Technical Analysis for AZTR - Azitra Inc.

    Grade Last Price % Change Price Change
    F 3.40 22.92% 0.63
    AZTR closed up 22.92 percent on Monday, July 1, 2024, on 1.95 times normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical AZTR trend table...
    Date Alert Name Type % Chg
    Stochastic Buy Signal Bullish 0.00%
    Lower Bollinger Band Walk Weakness 0.00%
    New 52 Week Low Weakness 0.00%
    Wide Bands Range Expansion 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    New 52 Week Closing Low Bearish 22.92%
    New 52 Week Low Weakness 22.92%
    Wide Bands Range Expansion 22.92%
    Below Lower BB Weakness 22.92%
    Older End-of-Day Signals for AZTR ...

       Recent Intraday Alerts

    Alert Time
    Rose Above Lower Bollinger Band about 9 hours ago
    2x Volume Pace about 9 hours ago
    1.5x Volume Pace about 9 hours ago
    3x Volume Pace about 9 hours ago
    Down 5% about 9 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    AZTR Chart by TradingView
    Basic chart:

    Profile

    Azitra Inc, a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Cancer Life Sciences Molecular Biology Rare Diseases Epidermal Growth Factor Receptor Genodermatoses Skin Diseases Netherton Syndrome Pre Clinical Biopharmaceutical Biotherapeutic Products Ichthyosis

    Is AZTR a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 27 Azitra announces 1-for-30 reverse stock split
    Jun 27 Azitra, Inc. Announces Reverse Stock Split
    Jun 17 AZTR: Historical and Financial Review
    Jun 6 AZTR: Netherton Syndrome Review and ATR-12 Clinical Trial
    Jun 3 AZTR: Pipeline Review
    May 31 Azitra, Inc. Announces Presentation at the 2024 BIO International Convention
    May 17 Azitra, Inc. Announces Positive Preclinical Data from ATR-04 Presented at the Society of Investigative Dermatology Annual Meeting
    May 10 Azitra GAAP EPS of -$0.15
    May 10 Azitra, Inc. Announces Positive Preclinical Data of ATR-12 and Clinical Design in Netherton Syndrome Presented at the ASGCT Annual Meeting
    May 9 Azitra, Inc. Announces Q1 2024 Financial Results and Provides Business Updates
    See more AZTR news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 129.795
    52 Week Low 2.52
    Average Volume 79,718
    200-Day Moving Average 24.81
    50-Day Moving Average 5.59
    20-Day Moving Average 4.45
    10-Day Moving Average 4.15
    Average True Range 0.89
    RSI (14) 83.58
    ADX 23.25
    +DI 7.84
    -DI 24.91
    Chandelier Exit (Long, 3 ATRs) 5.70
    Chandelier Exit (Short, 3 ATRs) 5.20
    Upper Bollinger Bands 6.16
    Lower Bollinger Band 2.75
    Percent B (%b) 0.19
    BandWidth 76.59
    MACD Line -0.63
    MACD Signal Line -0.53
    MACD Histogram -0.1065
    Fundamentals Value
    Market Cap 41.13 Million
    Num Shares 12.1 Million
    EPS -1.23
    Price-to-Earnings (P/E) Ratio -2.76
    Price-to-Sales 22.01
    Price-to-Book 2.59
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 4.83
    Resistance 3 (R3) 4.69 4.08 4.59
    Resistance 2 (R2) 4.08 3.72 4.15 4.51
    Resistance 1 (R1) 3.74 3.49 3.91 3.88 4.43
    Pivot Point 3.13 3.13 3.22 3.20 3.13
    Support 1 (S1) 2.79 2.77 2.96 2.93 2.37
    Support 2 (S2) 2.18 2.54 2.25 2.29
    Support 3 (S3) 1.84 2.18 2.21
    Support 4 (S4) 1.98